View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry


A Program for Chief Medical Officers in Emerging Life Sciences, November 3-4, 2014

  • October 21, 2014

  • The role of a Chief Medical Officer is one that takes courage given the numerous hats worn simultaneously. For a CMO in early, emerging and even midsize life science companies, it can be a solitary one. In addition to the responsibilities of driving clinical development, drug safety, medical affairs, regulatory strategy and CRO management, CMOs may also need to meet the needs of investors and help position for an appropriate exit.

    On November 3-4 in San Francisco, our team is hosting a program designed for CMOs of Emerging Biotechs thanks to an idea suggested by Dr Elizabeth Stoner, Managing Director, MPM Capital. The program is dedicated to accomplishing two goals:

    1. To bring together CMO executives to address the unique challenges associated with directing and managing all R&D functions with limited resources, while raising capital, working and meeting with investors, and strategizing for appropriate exits.

    2. To create a network of CMOs from small to midsize life science companies to share ideas, solutions and support.

    Chaired by Dr Lee Allen, CMO, Spectrum Pharmaceuticals 
and Dr Pamela Palmer, CMO & Co-Founder, AcelRX Pharmaceuticals, Inc., the keynotes include:

    The Jazz Pharmaceutical Turn Around Case Study
    Dr Jeffrey Tobias, EVP, R&D & CMO, Jazz Pharmaceuticals

    Life of a CMO Pre and Post IPO
    Dr Jakob Dupont, CMO & SVP, OncoMed


    Regulatory Approval and Market Access in Europe
    Dr Thomas Lonngren, 
Former Head, EMA

    The program also includes an entire afternoon on alternative clinical designs led by Onyx Pharmaceuticals. For more information on the CMOW event, please visit